The crystal structure of NAD(P)H quinone oxidoreductase 1 in complex with its potent inhibitor dicoumarol.
暂无分享,去创建一个
O. Dym | Y. Shaul | P. Tsvetkov | G. Asher | J. Adler | Peter Tsvetkov | Gad Asher
[1] 刘金明,et al. IL-13受体α2降低血吸虫病肉芽肿的炎症反应并延长宿主存活时间[英]/Mentink-Kane MM,Cheever AW,Thompson RW,et al//Proc Natl Acad Sci U S A , 2005 .
[2] Y. Shaul,et al. p53 Proteasomal Degradation: Poly-Ubiquitination is Not the Whole Story , 2005, Cell cycle.
[3] J. Lotem,et al. Inhibition of NAD(P)H:quinone oxidoreductase 1 activity and induction of p53 degradation by the natural phenolic compound curcumin. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[4] Y. Shaul,et al. 20S proteasomal degradation of ornithine decarboxylase is regulated by NQO1. , 2005, Molecular cell.
[5] Y. Shaul,et al. A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. , 2005, Genes & development.
[6] Randy J Read,et al. Electronic Reprint Biological Crystallography Likelihood-enhanced Fast Rotation Functions Biological Crystallography Likelihood-enhanced Fast Rotation Functions , 2003 .
[7] J. Lotem,et al. p53-dependent apoptosis and NAD(P)H:quinone oxidoreductase 1. , 2004, Methods in enzymology.
[8] J. Lotem,et al. p53 hot-spot mutants are resistant to ubiquitin-independent degradation by increased binding to NAD(P)H:quinone oxidoreductase 1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[9] David Siegel,et al. Interaction of Human NAD(P)H:Quinone Oxidoreductase 1 (NQO1) with the Tumor Suppressor Protein p53 in Cells and Cell-free Systems* , 2003, The Journal of Biological Chemistry.
[10] J. Lotem,et al. Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1 , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[11] J. Lotem,et al. NQO1 stabilizes p53 through a distinct pathway , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[12] L. Amzel,et al. Characterization of a mechanism-based inhibitor of NAD(P)H:quinone oxidoreductase 1 by biochemical, X-ray crystallographic, and mass spectrometric approaches. , 2001, Biochemistry.
[13] J. Lotem,et al. Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[14] A. Jaiswal,et al. Role of NAD(P)H:quinone oxidoreductase 1 (DT diaphorase) in protection against quinone toxicity. , 2000, Biochemical pharmacology.
[15] L. Amzel,et al. Structures of recombinant human and mouse NAD(P)H:quinone oxidoreductases: species comparison and structural changes with substrate binding and release. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[16] D. Siegel,et al. NAD(P)H:Quinone Oxidoreductase Activity Is the Principal Determinant of β-Lapachone Cytotoxicity* , 2000, The Journal of Biological Chemistry.
[17] D. Siegel,et al. NAD(P)H:Quinone oxidoreductase activity is the principal determinant of beta-lapachone cytotoxicity. , 2000, The Journal of biological chemistry.
[18] C. S. Yang,et al. Molecular characterization of binding of substrates and inhibitors to DT-diaphorase: combined approach involving site-directed mutagenesis, inhibitor-binding analysis, and computer modeling. , 1999, Molecular pharmacology.
[19] R J Read,et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.
[20] Z. Otwinowski,et al. Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.
[21] L. Amzel,et al. The three-dimensional structure of NAD(P)H:quinone reductase, a flavoprotein involved in cancer chemoprotection and chemotherapy: mechanism of the two-electron reduction. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[22] J M Thornton,et al. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. , 1995, Protein engineering.
[23] J. Thornton,et al. PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .
[24] S. Chen,et al. Inhibition of NAD(P)H:quinone acceptor oxidoreductase by flavones: a structure-activity study. , 1993, Archives of biochemistry and biophysics.
[25] A. Y. Lu,et al. Identification of a glycine-rich sequence as an NAD(P)H-binding site and tyrosine 128 as a dicumarol-binding site in rat liver NAD(P)H:quinone oxidoreductase by site-directed mutagenesis. , 1992, The Journal of biological chemistry.
[26] P. Talalay,et al. Inhibition of NAD(P)H:(quinone-acceptor) oxidoreductase by cibacron blue and related anthraquinone dyes: a structure-activity study. , 1992, Biochemistry.
[27] J. Zou,et al. Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.
[28] D. Ross,et al. Metabolism of mitomycin C by DT-diaphorase: role in mitomycin C-induced DNA damage and cytotoxicity in human colon carcinoma cells. , 1990, Cancer research.
[29] E. Cadenas,et al. [30] DT-diaphorase : purification, properties, and function , 1990 .
[30] K. Hayashi,et al. Properties and reaction mechanism of DT diaphorase from rat liver. , 1974, The Journal of biological chemistry.
[31] W. Wosilait,et al. Comparative study of the binding of coumarin anticoagulants and serum albumins. , 1971, Biochemical pharmacology.